These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32867107)

  • 1. Follow-Up 18F-FDG PET/CT versus Contrast-Enhanced CT after Ablation of Liver Metastases of Colorectal Carcinoma-A Cost-Effectiveness Analysis.
    Schnitzer ML; Froelich MF; Gassert FG; Huber T; Gresser E; Schwarze V; Nörenberg D; Todica A; Rübenthaler J
    Cancers (Basel); 2020 Aug; 12(9):. PubMed ID: 32867107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of 18F-FDG PET/CT, MRI and CE-CT in selection of colorectal liver metastases eligible for ablation - A cost-effectiveness analysis.
    Schnitzer ML; Buchner J; Biechele G; Grawe F; Ingenerf M; von Münchhausen N; Kaiser CG; Kunz WG; Froelich MF; Schmid-Tannwald C; Rübenthaler J
    Eur J Radiol; 2023 Jun; 163():110803. PubMed ID: 37004464
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness analysis of MRI, CE-CT and 18F-FDG PET/CT for detecting colorectal liver metastases eligible for hepatic resection.
    Schnitzer ML; von Münchhausen N; Biechele G; Runtemund J; Grawe F; Geyer T; Kaiser CG; Haag F; Rübenthaler J; Froelich MF
    Front Oncol; 2023; 13():1161738. PubMed ID: 37554160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
    Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
    J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Gassert FG; Rübenthaler J; Cyran CC; Rink JS; Schwarze V; Luitjens J; Gassert FT; Makowski MR; Schoenberg SO; Mayerhoefer ME; Tamandl D; Froelich MF
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3268-3276. PubMed ID: 33686457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metastatic colorectal carcinoma: cost-effectiveness of percutaneous radiofrequency ablation versus that of hepatic resection.
    Gazelle GS; McMahon PM; Beinfeld MT; Halpern EF; Weinstein MC
    Radiology; 2004 Dec; 233(3):729-39. PubMed ID: 15564408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Effectiveness Analysis of
    Froelich MF; Schnitzer ML; Holzgreve A; Gassert FG; Gresser E; Overhoff D; Schwarze V; Fabritius MP; Nörenberg D; von Münchhausen N; Hokamp NG; Auernhammer CJ; Ilhan H; Todica A; Rübenthaler J
    Diagnostics (Basel); 2021 Feb; 11(2):. PubMed ID: 33670457
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation.
    Sivesgaard K; Larsen LP; Sørensen M; Kramer S; Schlander S; Amanavicius N; Bharadwaz A; Tønner Nielsen D; Viborg Mortensen F; Morre Pedersen E
    Eur Radiol; 2018 Nov; 28(11):4735-4747. PubMed ID: 29736846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Additional MRI for initial M-staging in pancreatic cancer: a cost-effectiveness analysis.
    Gassert FG; Ziegelmayer S; Luitjens J; Gassert FT; Tollens F; Rink J; Makowski MR; Rübenthaler J; Froelich MF
    Eur Radiol; 2022 Apr; 32(4):2448-2456. PubMed ID: 34837511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
    Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
    Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of 18F-FDG PET/CT on therapeutic decisions in patients with colorectal cancer and liver metastases.
    Georgakopoulos A; Pianou N; Kelekis N; Chatziioannou S
    Clin Imaging; 2013; 37(3):536-41. PubMed ID: 23116727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
    van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
    Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
    Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET/CT in indeterminate thyroid nodules: cost-utility analysis alongside a randomised controlled trial.
    de Koster EJ; Vriens D; van Aken MO; Dijkhorst-Oei LT; Oyen WJG; Peeters RP; Schepers A; de Geus-Oei LF; van den Hout WB;
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3452-3469. PubMed ID: 35435497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In patients with unprovoked VTE, does the addition of FDG PET/CT to a limited occult cancer screening strategy offer good value for money? A cost-effectiveness analysis from the publicly funded health care systems.
    Robin P; Kumar S; Salaun PY; Le Roux PY; Couturaud F; Planquette B; Merah A; Roy PM; Thavorn K; Le Gal G
    Thromb Res; 2018 Nov; 171():97-102. PubMed ID: 30268859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Supplemental
    Bicu F; Rink JS; Froelich MF; Cyran CC; Rübenthaler J; Birgin E; Röhrich M; Tollens F
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33803522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness Analysis of Local Ablation and Surgery for Liver Metastases of Oligometastatic Colorectal Cancer.
    Froelich MF; Schnitzer ML; Rathmann N; Tollens F; Unterrainer M; Rennebaum S; Seidensticker M; Ricke J; Rübenthaler J; Kunz WG
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806059
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET-Based Staging Is Cost-Effective in Early-Stage Follicular Lymphoma.
    Lo AC; James LP; Prica A; Raymakers A; Peacock S; Qu M; Louie AV; Savage KJ; Sehn LH; Hodgson D; Yang JC; Eich HTT; Wirth A; Hunink MGM
    J Nucl Med; 2022 Apr; 63(4):543-548. PubMed ID: 34413148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules.
    Gould MK; Sanders GD; Barnett PG; Rydzak CE; Maclean CC; McClellan MB; Owens DK
    Ann Intern Med; 2003 May; 138(9):724-35. PubMed ID: 12729427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.